{"id":"NCT01254188","sponsor":"Novartis Pharmaceuticals","briefTitle":"Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients","officialTitle":"Extending Molecular Responses With Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients in Chronic Phase","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04","primaryCompletion":"2014-11","completion":"2014-11","firstPosted":"2010-12-06","resultsPosted":"2016-03-03","lastUpdate":"2016-03-03"},"enrollment":421,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Myeloid Leukemia"],"interventions":[{"type":"DRUG","name":"Nilotinib","otherNames":["AMN107"]}],"arms":[{"label":"Nilotinib","type":"EXPERIMENTAL"}],"summary":"This study will further investigate the safety and efficacy of nilotinib in newly diagnosed chronic myeloid leukemia patients in the chronic phase","primaryOutcome":{"measure":"The Percentage of Patients Achieving MMR by 12 Months","timeFrame":"12 months","effectByArm":[{"arm":"Nilotinib","deltaMin":70.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":6},"locations":{"siteCount":100,"countries":["Algeria","Argentina","Australia","Brazil","Canada","Egypt","India","Israel","Lebanon","Malaysia","Mexico","Oman","Russia","Saudi Arabia","South Africa","Taiwan","Thailand","Tunisia","United Arab Emirates"]},"refs":{"pmids":["28699641"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":97,"n":421},"commonTop":["THROMBOCYTOPENIA","HEADACHE","RASH","LIPASE INCREASED","NAUSEA"]}}